We are Growing.

In 2015 we partnered with Water Street Healthcare Partners, a strategic investor
with extensive pharmaceutical expertise, to accelerate Custopharm’s growth. Since then,
we have built a scientific team to develop and commercialize complex sterile injectable
pharmaceutical products. With many new products in development and pending approval
with FDA we expect to significantly grow our commercial operations as we move forward.

Our goal is to become a US leader in generic injectable products. Together with Water Street, we are investing heavily to expand our operations, enhance our scientific personnel, and to pursue new partnerships and product acquisitions. We are confident that Custopharm will dramatically increase its role in bringing important new generic injectable products to market.

Custopharm has assembled a highly experienced team of industry executives to lead and grow our company. Our executive team has deep expertise in sterile injectable pharmaceutical products and a strong track record of success.

Leadership

William (Bill) has nearly 30 years of experience in the pharmaceutical industry. Prior to joining Custopharm and creating Leucadia Pharmaceuticals, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Prior to Bedford Laboratories he held various scientific leadership positions at Amylin, Novartis, ESI-Lederle, and Barr Laboratories. He began his career as an analytical research chemist at Zeneca Pharmaceuticals. Bill holds a PhD degree in Analytical Chemistry from The Ohio State University and a Bachelor of Science degree in Chemistry from Purdue University.

Jeff is responsible for overall financial operations, information technology, and human resources. He brings over 25 years of relevant experience, including significant experience in the public and private healthcare and life sciences companies. His most recent experience includes work for medical device and biotechnology companies, encompassing IPO readiness, M&A and significant restructuring activities. Prior to joining Custopharm, Jeff was the Chief Financial Officer of Digirad, a publicly traded healthcare services and medical device company, where he helped grow revenues significantly through a series of acquisitions and restructuring. Prior to this, Jeff held senior financial roles at Sapphire Energy, Advanced BioHealing (sold to Shire for $750 million) and CareFusion (sold to Becton Dickinson). Jeff holds a bachelor’s degree in accounting and economics, and is a Certified Public Accountant in the state of Washington.

Junan has more than 24 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Junan was vice president of global quality at TWi Pharmaceuticals, where he oversaw quality operations in the areas of oral dosage and sterile products. Previously, he was vice president of quality at Catalent and AMRI, held quality responsibility in north America, south America, Europe, and Asia Pacific. Junan has also held pharmaceutical development leadership positions at AMRI, Patheon, and Mylan. Junan earned his doctorate degree in physical organic chemistry from Western University in Canada.

David has more than 20 years of pharmaceutical experience. Prior to joining Custopharm, David was Vice President of Regulatory Affairs at Amerigen Pharmaceuticals, Senior Director of Regulatory Affairs at Anchen Pharmaceuticals (part of Par Pharmaceuticals) and held regulatory affairs positions at Watson Laboratories (now Actavis Inc.). David has extensive experience with obtaining FDA approval of complicated, high barrier, first-to-file/first-to-market generic products. David has also worked at Loma Linda University in the School of Medicine performing preclinical drug development. David earned his Masters of Science in Biology from California State University.

Mohammad has more than 30 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Mohammad has successfully managed manufacturing, engineering and technology transfer functions in regulated cGMP environments. He has extensive knowledge and experience in process development and manufacturing of small and large molecule parenteral products, including biologics, suspensions, emulsions and liposomes in liquid and lyophilized dosage forms. Mohammad in past has held positions with increasing responsibilities at Boehringer Ingelheim (BenVenue Lab), Baxter Biopharma Solutions and Fresenius Kabi (American Pharmaceutical Partners). Mohammad holds a Master’s degree in Industrial Engineering from University of Cincinnati and Bachelor’s degree in Mechanical Engineering from NED University of Engineering.

Custopharm has assembled a highly experienced team of industry executives to lead and grow our company. Our executive team has deep expertise in sterile injectable pharmaceutical products and a strong track record of success.

Leadership

William (Bill) has more than 27 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Previously, he was senior director of product development at Amylin Pharmaceuticals Inc., where he managed development activities for proprietary peptide and protein injectable products. Bill also held positions at Novartis, ESI-Lederle, Barr Laboratories, Inc. and Schein Pharmaceutical, Inc. He began his career as an analytical research chemist. Bill received a doctorate degree in analytical chemistry from The Ohio State University and a bachelor’s degree in chemistry from Purdue University.

Jeff is responsible for overall financial operations, information technology, and human resources. He brings over 25 years of relevant experience, including significant experience in the public and private healthcare and life sciences companies. His most recent experience includes work for medical device and biotechnology companies, encompassing IPO readiness, M&A and significant restructuring activities. Prior to joining Custopharm, Jeff was the Chief Financial Officer of Digirad, a publicly traded healthcare services and medical device company, where he helped grow revenues significantly through a series of acquisitions and restructuring. Prior to this, Jeff held senior financial roles at Sapphire Energy, Advanced BioHealing (sold to Shire for $750 million) and CareFusion (sold to Becton Dickinson). Jeff holds a bachelor’s degree in accounting and economics, and is a Certified Public Accountant in the state of Washington.

Junan has more than 24 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Junan was vice president of global quality at TWi Pharmaceuticals, where he oversaw quality operations in the areas of oral dosage and sterile products. Previously, he was vice president of quality at Catalent and AMRI, held quality responsibility in north America, south America, Europe, and Asia Pacific. Junan has also held pharmaceutical development leadership positions at AMRI, Patheon, and Mylan. Junan earned his doctorate degree in physical organic chemistry from Western University in Canada.

David has more than 20 years of pharmaceutical experience. Prior to joining Custopharm, David was Vice President of Regulatory Affairs at Amerigen Pharmaceuticals, Senior Director of Regulatory Affairs at Anchen Pharmaceuticals (part of Par Pharmaceuticals) and held regulatory affairs positions at Watson Laboratories (now Actavis Inc.). David has extensive experience with obtaining FDA approval of complicated, high barrier, first-to-file/first-to-market generic products. David has also worked at Loma Linda University in the School of Medicine performing preclinical drug development. David earned his Masters of Science in Biology from California State University.

Mohammad has more than 25 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Mohammad has successfully managed manufacturing, engineering and technology transfer functions in regulated cGMP environments most recently with West Ward Pharmaceuticals. He has extensive knowledge and experience in process development and manufacturing of small and large molecule parenteral products, including biologics, nanoparticle suspensions, emulsions, liposome, liquid and lyophilized dosage forms packaged in vials, syringe, cartridges and bags. Mohammad in past has held positions with increasing responsibilities at Ben Venue Labs, Baxter Biopharma Solutions, American Pharmaceutical Partners and DOW Chemical Co. Mohammad received his Master’s degree in Industrial Engineering from University of Cincinnati and Bachelor’s degree in Mechanical Engineering from NED University of Engineering.

Board of Directors

William (Bill) has more than 27 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Previously, he was senior director of product development at Amylin Pharmaceuticals Inc., where he managed development activities for proprietary peptide and protein injectable products. Bill also held positions at Novartis, ESI-Lederle, Barr Laboratories, Inc. and Schein Pharmaceutical, Inc. He began his career as an analytical research chemist. Bill received a doctorate degree in analytical chemistry from The Ohio State University and a bachelor’s degree in chemistry from Purdue University.

Al Heller is the former president and CEO of American Pharmaceutical Partners Inc. (APPI), a leading manufacturer of multi-source and branded injectable pharmaceutical products. He also was senior vice president and president of Global Renal Operations for Baxter International, where he led global operations for the Renal and Transfusion Therapies divisions, global manufacturing and the Office of the Chief Scientific Officer. Al began his career at G.D. Searle. During his 23 years with the company, he was promoted to numerous positions, including co-president and COO, and executive vice president and president of Searle Operations. Al currently serves as an operating partner with Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He received his bachelor’s degree from the University of Illinois, Chicago and his master’s degree in business administration from DePaul University.

Dave is the co-founder of Custopharm, Inc, currently serving as Vice Chairman of the Board. Accomplished pharmaceutical executive with 33 years of experience encompassing executive management and strategic business development in a growing and changing global environment. Outstanding record of leadership and achievement in enhancing productivity, reducing costs and increasing profitability, successfully managed sales departments at Warner Lambert, Regis Technologies, Inc., Chemwerth, Inc., and Custopharm, Inc. David holds a Bachelor of Business Administration from the Iowa State University.

Dan Robins is former vice president of global development for Mylan, where he was responsible for injectable products. His former business, Bioniche Pharma, where he led research and development in Ireland, was acquired by Mylan in 2010. Prior to Bioniche Pharma, Dan was vice president of product development for Abraxis BioScience (formerly American Pharmaceutical Partners Inc.) He also held leadership positions at Barr Laboratories, Inc. and scientific roles at Schering-Plough Research Institute, Mallinckrodt Veterinary and Pentech Pharmaceuticals. Dan received master’s and doctorate degrees in chemistry from The Ohio State University and his master’s degree in business administration from New York University. He earned his bachelor’s degree from LaSalle University.

Peter Strothman has spent his career investing in the healthcare and private equity industries. He invests and creates value in companies specializing in life sciences, specialty pharmaceutical products and services, and general healthcare products and outsourced services. As a partner with Water Street, Peter has built a leading group of pharmaceutical companies. Prior to joining Water Street, Peter was a principal with JLL Partners, where he focused exclusively on healthcare investments. He began his career in the Global Mergers and Acquisitions group of Lehman Brothers. Peter received a bachelor’s degree in economics from Harvard University.

George Zorich has more than 30 years of pharmaceutical industry experience. Most recently, he served as chief executive officer of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich’s ataxia. Previously, George was president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products that was sold to Mylan Pharmaceuticals. George also was president of Sabex-USA, which was sold to Sandoz, where he led the Sandoz U.S. injectable business. Prior to that, he was president of GIV, which was the largest distributor of vaccines to physician offices. George also held executive positions at Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories and Eli Lilly and Company. He is a board member of the American Society of HealthSystem Pharmacists Foundation and serves on the University of Wisconsin School of Pharmacy Board of Visitors. George received his pharmacy degree from the University of Wisconsin.

We are currently recruiting for a number of career opportunities, including: analytical and formulation scientists, project managers, regulatory associates, financial analysts, and laboratory and office assistants. If you are interested in becoming part of an entrepreneurial, growing organization, please click here to review our positions and submit your resume.

Looking Ahead

Custopharm is actively pursuing new product and partnership opportunities. We are looking to acquire sterile injectable products, strategically partner with development and manufacturing companies, and provide enhanced support for our regulatory services partners.

If you are interested in opportunities to partner with Custopharm, please click here to submit your contact information.